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Abstract
Background: Serine-threonine kinases of the Raf family (A-Raf, B-Raf, C-Raf) are central players
in cellular signal transduction, and thus often causally involved in the development of cancer when
mutated or over-expressed. Therefore these proteins are potential targets for immunotherapy and
a possible basis for vaccine development against tumors. In this study we analyzed the functionality
of a new live C-Raf vaccine based on an attenuated Salmonella enterica serovar Typhimurium aroA
strain in two Raf dependent lung tumor mouse models.
Methods: The antigen C-Raf has been fused to the C-terminal secretion signal of Escherichia coli
α-hemolysin and expressed in secreted form by an attenuated aroA Salmonella enterica serovar
Typhimurium strain via the α-hemolysin secretion pathway. The effect of the immunization with
this recombinant C-Raf strain on wild-type C57BL/6 or lung tumor bearing transgenic BxB mice
was analyzed using western blot and FACS analysis as well as specific tumor growth assays.
Results: C-Raf antigen was successfully expressed in secreted form by an attenuated Salmonella
enterica serovar Typhimurium aroA strain using the E. coli hemolysin secretion system. Immunization
of wild-type C57BL/6 or tumor bearing mice provoked specific C-Raf antibody and T-cell
responses. Most importantly, the vaccine strain significantly reduced tumor growth in two
transgenic mouse models of Raf oncogene-induced lung adenomas.
Conclusions: The combination of the C-Raf antigen, hemolysin secretion system and Salmonella
enterica serovar Typhimurium could form the basis for a new generation of live bacterial vaccines
for the treatment of Raf dependent human malignancies.
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Background
The Raf proteins (A-Raf, B-Raf, C-Raf) are located
upstream of MEK and downstream of Ras and represent
an essential part of the mitogenic cascade [1-3]. Interest-
ingly, Raf kinases are not only central players in cellular
signal transduction, but are often causally involved in the
development of cancer. Recently, B-Raf was found to be
mutated in a broad range of malignancies including
melanoma (more than 65%), and colon cancer [4]. In
addition, overexpression of C-Raf was found in many
tumors [5,6]. Therefore, these proteins are potential tar-
gets for immunotherapy as well as immunoprevention of
tumors.
Here we describe the development of a C-Raf vaccine on
the basis of an attenuated Salmonella enterica serovar
Typhimurium aroA strain. Such recombinant live vaccines
have been shown to efficiently elicit both, humoral and
cellular immune responses against a variety of heterolo-
gous antigens [7,8]. In order to achieve stable expression
of C-Raf we used the E. coli α-hemolysin (HlyA) secretion
system which is fully active in Salmonella [9]. This trans-
port machinery is the prototype of type I secretion systems
and consists of three different components, namely HlyB,
HlyD and TolC. The HlyA carries at its C-terminus a secre-
tion signal of about 50–60 amino acids in length (HlyAs),
which is recognized by the HlyB/HlyD/TolC-translocator,
leading to direct secretion of the entire protein into the
extracellular medium without the formation of periplas-
mic intermediates. In addition, fused to the C-terminus of
heterologous proteins, the HlyAs leads to efficient secre-
tion of such proteins by the recombinant bacteria. In our
case, the whole C-Raf antigen fused to the C-terminal
secretion signal of hemolysin was efficiently expressed
and secreted by an attenuated Salmonella enterica serovar
Typhimurium aroA strain. The effects of this recombinant
vaccine were assessed in wild-type C57BL/6 or tumor
bearing transgenic BxB mice.
Methods
Bacterial strains, plasmids, cell lines and mice
The bacterial strains, plasmids, cell lines and mice used in
this study are listed in Table 1.
Plasmid transformation in Salmonella enterica serovar 
Typhimurium SL7207
The plasmids pMOhly1 and pMOhly-Raf were first trans-
formed in competent Salmonella enterica serovar Typh-
imurium LB5000 (Tab. 1), a restriction-negative and
modification-proficient strain by a standard transforma-
tion protocol for E. coli [10,11]. Subsequently, the plas-
mids purified from Salmonella enterica serovar
Typhimurium LB5000 were introduced into Salmonella
enterica serovar Typhimurium SL7207 by electroporation
using a Bio-Rad Gene Pulser (Hercules, CA, USA) at 2.5
kV, 25 microfarads (µF), and 200 Ohm in a 0.1 cm elec-
troporation cuvette.
Construction of the plasmid pMOhly-Raf
Sense primer 5' Raf: 5'-ATGGAGCACATACATGCATCTT-
GGAAG-3' and antisense primer 3'Raf: 5'-CAACTAGAAT-
GCATGCAGCCTCGGGGA-3' were used to amplify by
PCR a 1950 bp DNA fragment representing the entire craf
gene from plasmid pUC13-c-raf-1 [12]. PCRs were per-
formed in a Thermal Cycler 60 (Biometra, Göttingen, Ger-
many) for 30 cycles of 94°C for 1 min, 55°C for 1 min,
and 72°C for 90 s. After purification with the GeneClean
Kit (Bio101, La Jolla, Ca) and digestion with the NsiI
restriction enzyme, the DNA fragment carrying the craf
gene was inserted into the single NsiI site of the export vec-
tor pMOhly1 [13]. The resulting plasmid pMOhly-Raf was
isolated from E. coli DH5α (Invitrogen), analyzed and
transformed in S. typhimurium SL7207 (Tab. 1) by
electroporation.
Western blot analysis
Salmonella enterica serovar Typhimurium strains harbour-
ing the recombinant plasmids pMOhly1 or pMOhly-Raf
were cultivated at 37°C in BHI medium with 100 µg/ml
ampicillin. Cells at the exponential growth phase (OD600
of 1) were centrifuged at 5000 × g at 4°C for 5 min. The
supernatant proteins were precipitated with 10% (V/V)
trichloroacetic acid (TCA) for 1 h on ice, collected by cen-
trifugation and resuspended in SDS sample buffer. The
supernatant proteins were separated on 10% gels by SDS-
PAGE [14]. For immunodetection of Raf-HlyA proteins
the rabbit polyclonal anti-Raf antibody SP-63 (diluted
1:1,000, Rapp Laboratory) and donkey anti-rabbit immu-
noglobulins linked to horseradish peroxidase (Amersham
Pharmacia Biotech) diluted 1:1,000 as secondary antibod-
ies were used. Blots were developed by enhanced chemi-
luminescence (ECL reagents; Amersham Biosciences, UK)
and exposed on X-ray film (Kodak, XO-MAT-AR) for 1
min.
Immunization of mice with Salmonella enterica serovar 
Typhimurium SL7207 strains
Oral/intravenous prime boost protocol (p.o./i.v.)
In order to achieve a broad immune response encompass-
ing both, the mucosal and systemic immunity against C-
Raf, we combined oral immunization (p.o.) with an intra-
venous (i.v.) boost. In these experiments, seven weeks old
C57BL/6 or BxB23 mice were immunized, first p.o. three
times with 5 × 109 bacteria/100  µl phosphate-bufferd
saline (PBS) at 5-day intervals. At day 45 after the start of
the vaccination, these mice were boosted intravenously
(i.v.) with a single-dose of 5 × 105 bacteria/100 µl PBS.
The BxB23 mice received a second i.v. boost of 5 × 105 bac-
teria at day 90 after the start of the vaccination. InductionBMC Cancer 2005, 5:15 http://www.biomedcentral.com/1471-2407/5/15
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of Raf-specific immune responses were analyzed at day 50
for C57BL/6 or at day 95 for BxB23 respectively.
Intranasal Immunization (i.n.)
Seven weeks old BxB23 mice were immunized i.n. four
times with 1 × 107bacteria/30  µl phosphate-buffered
saline (PBS) at 14-day intervals. The vaccine was applied
using a micropipette onto the nares of mice under
anesthesia.
Induction of Raf-specific immune responses were ana-
lyzed at day 70.
I. n. Immunization of BXB11 mice with Salmonella enterica serovar 
Typhimurium SL7207/pMOhly-Raf
Four months old BXB11 mice were immunized i.n. three
times with 1 × 108salmonellae in 10 µl PBS at 14-day
intervals. The vaccine was applied using a micropipette
into the nares of mice without anesthesia.
Construction of a C-Raf overexpressing EL-4 cell line
In order to create tools for analysis of C-Raf specific T cells
we first constructed a C-Raf overexpressing EL-4 cell line
(ELRaf). The EL4 tumor cell line is a murine thymoma cell
line of the H-2b haplotype (Tab. 1). 10 µg purified DNA of
plasmid pDNA3craf was introduced into EL4 cells by elec-
troporation with the Bio-Rad Gene Pulser (Hercules, CA)
at 0.25 kV, 960 µFD, in a 0.4-cm electroporation cuvette.
The transformed cells were grown RPMI 1640 medium
(Invitrogen) supplemented with 5% (vol/vol) FCS (PAN
Systems) and 600 µg/ml G418 (Sigma). C-Raf is highly
expressed in ELRaf cells (data not shown).
Flow cytometric detection of specific CD8+ T-cells
Isolation of spleen cells
Animals were sacrificed and a single cell suspension of
splenocytes was prepared by passage of the spleen
through a sieve into RP 10 medium [RPMI medium (Life
Technologies) supplemented with glutamine (1%), 50
µM  β-mercaptoethanol (ROTH, Wuerzburg), penicillin
(10 U/ml, GIBGO), streptomycin (100 U/ml, GIBGO)
and 10% fetal calf serum (PAN™, BIOTECH GmbH).
The cell suspension was centrifuged and resuspended in 3
ml lysis buffer (5 mM Tris-HCl, 140 mM NH4Cl, pH 7.3)
for the lysis of erythrocytes. After 2 minutes, 10 ml RP 10
medium was added to stop lysis. After centrifugation, cells
were resuspended in 2 ml RP 10 medium and counted.
Table 1: Bacterial strains, plasmids (ApR-ampicillin-resistant), cell lines and mice
Name Relevant characteristics/sequence Source or reference
Bacterial strains:
E. coli DH5α F-, ø80dlacZ∆M15, ∆(lacZYA-argF)U169 deoR, recA1, endA1, 
hsdR17(rk-, mk+), phoA, supE44, λ-, thi-1, gyrA96, relA1
Takaba
Salmonella enterica serovar
Typhimurium aroA SL7207 hisG46, DEL407 [aroA544::Tn10 (Tcs)] Stocker, B. A. D.
Salmonella enterica serovar
Typhimurium LB5000 rk-, mk+ Stocker, B. A. D.
Plasmids:
pUC13-c-raf-1 c-raf cDNA in pUC13 [12]
pcDNA3 pCMV, ApR, Neomycin, SV 40, ColE Invitrogene
pcDNA-craf craf cDNA in pcDNA3 Troppmair, J
pMOhly1 ApR, hlyR, hlyC, hlyAs (encoding the hemolysin secretion signal), 
hlyB, hlyD
[13]




EL-4 spontaneous murine lymphoma ATCC(Rockville, MD, USA)
EL-4Raf pcDNA-craf transfected EL-4 cells this study
SF9 insect cell line Gibco
SF9 Raf craf transfected SF9 cells [28]
Mice:
C57BL/6JolaHsd wild-type (H-2b) Harlan-Winkelmann, Borche, Germany
BxB23 [(C57BL/6 × DBA-2)F1] expressing an oncogenically activated 
NH2-terminal deletion mutant c-Raf-1-BxB under the control of 
human SP-C promoter
[15]
BxB11 [(C57BL/6 × DBA-2)F1] expressing an oncogenically activated 
NH2-terminal deletion mutant c-Raf-1-BxB under the control of 
human SP-C promoter
[15]BMC Cancer 2005, 5:15 http://www.biomedcentral.com/1471-2407/5/15
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Restimulation
In 6 ml FACS tubes and a total volume of 100 µl RP 10
medium in the presence of 30 U/ml recombinant IL-2 and
10 µg/ml Brefeldin A at 37°C, 5% CO2, 1 × 106 spleen
cells were incubated for 5 hours with 5 × 105 C-Raf over-
expressing EL-4 cells (EL-Raf) or 5 × 105 EL-4 cells or with
the addition of 10 ng/ml of phorbol myristyl acetate
(PMA; Sigma) and 500 ng/ml of ionomycin (Sigma) or
with medium alone.
Staining
After restimulation, cells were washed with PBS-0.1%
bovine serum albumin (BSA; P-B buffer) and incubated
with 1 µl of anti-CD8-CyChrome (Pharmingen Nr.
01082A) in a volume of 100 µl PBS-0.1% BSA for 20 min
on ice. Subsequently, cells were washed and fixed for 20
min at room temperature with PBS-2% paraformaldehyde
(Sigma). After washing with PBS-0.1% (BSA), cells were
permeabilized with PBS-0.1% BSA-0.5% saponin (Sigma,
P-B-S) buffer. After incubation for 5 min at room temper-
ature, cells were washed with P-B-S buffer and incubated
in a volume of 100 µl at room temperature with polyclo-
nal rat immunoglobulin G (IgG) antibodies (JacksonIm-
munoResearch) to block nonspecific binding and 1 µl
anti-IFN-γ-FITC (AN18.17.24; XMG1.2 Rat IgG1;
Pharmingen) for 20 min. After incubation, cells were
washed twice with P-B-S buffer and another time with P-
B buffer. Cells were resuspended in 400 µl PBS-PFA 0,5%
and kept at 4°C until analysis.
Analysis
Cells were analyzed by flow cytometry in a FACS Calibur
flow cytometer (Becton Dickinson) using CellQuest 3.0
software (Becton Dickinson). Lymphocytes were chosen
according to their size and granularity in a forward/side –
scatter diagram. Numbers are expressed as percent IFN-γ
positive CD8+ cells.
Statistical analysis
The statistical significance of differential findings between
experimental groups was determined by Student's t test.
Findings were regarded as significant, if P  values were
<0.05. Survival curves were compared using a log rank
test.
Results
Creation of a C-Raf vaccine on the basis of the attenuated 
Salmonella enterica serovar Typhimurium strain SL7207
The construction of the attenuated Salmonella enterica
serovar Typhimurium aroA strain SL7207 secreting the C-
Raf antigen was achieved by cloning the human craf cDNA
from pUC13-c-raf-1 [12] into the vector plasmid
pMOhly1 [13] as described in materials and methods. The
resulting plasmid pMOhly-Raf carried the craf-hlyAs fused
gene and the functional hlyB and hlyD genes required for
its secretion (Fig. 1). The S. typhimurium SL7207/pMOhly-
Raf strain efficiently expressed and secreted the hybrid C-
Raf protein, as shown by immunoblotting with polyclo-
nal antibodies raised against C-Raf (Fig. 2). The amount of
secreted C-Raf was 2–3 µg protein/ml supernatant under
the experimental conditions.
Raf-specific responses of mice after immunization with 
recombinant SL7207/pMOhly-Raf
The efficacy of the recombinant bacterial strain to induce
a Raf-specific immune response was analyzed using wild-
type C57BL/6 and transgenic BxB23 mice. Groups of five
C57BL/6 and BxB23 mice at the age of 7 weeks were
immunized p.o./i.v or i.n. with recombinant Salmonella
enterica  serovar Typhimurium SL7207 secreting C-Raf
antigen (SL7207/pMOhly-Raf) and with Salmonella enter-
ica serovar Typhimurium SL7207 as control in order to
test the induction of Raf-specific immune responses. The
data showed that 20% of the sera of BxB23 mice immu-
nized with SL7207/pMOhly-Raf contained Raf-specific
antibodies (Fig. 3; supplementary Fig. 1 [see Additional
file 1]). In contrast, no Raf-specific IgG response was
detectable in the sera of BxB23 mice immunized with
SL7207 alone (data not shown). Similar data were
obtained after immunization of C57BL/6 mice with
SL7207/pMOhly-Raf and SL7207 (data not shown).
To assess the induction of Raf-specific T-cell responses,
mice were sacrificed and Raf specific T-cell responses were
assessed using intracellular IFN-γ staining followed by
FACS analysis. For this purpose, T-cells were restimulated
with C-Raf overexpressing EL-4 cells. Using this tech-
nique, we could detect Raf specific CD8+ T-cell response in
C57BL/6 animals immunized p.o./i.v. with SL7207/
pMOhly-Raf only but not in mice immunized i.n. or with
the control strain SL7207 (Fig. 4). In immunized BxB23
mice, but not naïve BxB23 mice, a high background and
variability of CD8+ IFN-γ positive cells even with non-spe-
cific stimulation was observed in two independent exper-
iments. Therefore it was not possible to assess specific T-
cell responses in this setting. Interestingly, the level of T-
cells which responded to polyclonal stimulation by PMA
/ ionomycin was also reduced about 4 fold in comparison
to C57BL/6 mice (data not shown).
Salmonella enterica serovar Typhimurium SL7207/
pMOhly-Raf strain induced partial protection against lung 
cancer in transgenic mouse models of Raf oncogene-
induced lung adenomas
To test the protective capacity of the immune responses
induced by the recombinant Salmonella strains, groups of
6 to 10 heterozygous BxB23 mice at the age of 7 weeks
were immunized p.o./i.v. or i.n. with recombinant Salmo-
nella enterica serovar Typhimurium strain (SL7207/
pMOhly-Raf) or with SL7207 as control. BxB23 miceBMC Cancer 2005, 5:15 http://www.biomedcentral.com/1471-2407/5/15
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normally show an induction of lung adenomas with short
latency and at 100% incidence [15,16]. The development
of lung adenomas in the vaccinated BxB23 mice was
assessed for 13 months. Our analysis revealed a
significantly delayed tumor growth (reduction of lung
weight) in mice immunized i.n. or p.o./i.v. with SL7207/
pMOhly-Raf compared to control mice (Fig. 5).
In order to confirm these data we repeated the protection
experiments using BxB11, another craf transgenic strain,
which develop lung adenomas after a shorter latency
Restriction map of plasmid pMOhly-Raf Figure 1
Restriction map of plasmid pMOhly-Raf The plasmid pMOhly-Raf contains the intact structural genes hlyC, hlyB and hlyD of the 
hemolysin operon and the c-raf-hlyA fusion hybrid gene. All genes are transcribed from the original cis-acting expression sites in 
front of hlyC [27]. Abbreviations: ori – origin of replication, bla – ampicillin resistance cassetteBMC Cancer 2005, 5:15 http://www.biomedcentral.com/1471-2407/5/15
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period compared to BxB23 mice [15]. In this case, 66% of
the mice immunized with SL7207/pMOhly-Raf survived
at least three months longer than the control mice (Fig. 6).
These results suggest that the immunization with the vac-
cine strain SL7207/pMOhly-Raf can achieve a partial pro-
tection against tumor growth in the BxB mouse model.
Discussion
The major problems for vaccine development against can-
cer are the heterogeneity of the tumor cells and the fact
that all tumor antigens are self-antigens. Therefore specific
T-cells might be anergic or tolerant [17,18].
However, despite these problems, several cancer vaccines
have already reached clinical trials [19]. The success of
these vaccines seems to be dependent on the target anti-
gen and on the tumor type.
Here we describe a new strategy for achieving an anti-
tumor immune response with a C-Raf vaccine on the basis
of an attenuated Salmonella enterica serovar Typhimurium
aroA strain as a "live vaccine". In general, recombinant
aroA salmonellae are efficient live bacterial vectors that
stimulate strong mucosal immunity, humoral and cell-
mediated responses with a great potential as live vaccine
carriers in both humans and animals [7,20]. Advantages
of live attenuated aroA Salmonella vaccines include their
safety and easy administration [21,22]. In addition aroA
Salmonella enterica serovar Typhimurium strains were
already successfully used as carriers for DNA vaccines
against cancer in mice [23].
In this study the C-Raf antigen was delivered in secreted
form by attenuated Salmonella enterica serovar Typhimu-
rium  aroA  strain using the E. coli hemolysin secretion
system. This system allows an efficient antigen secretion
and presentation, which are necessary for an optimal
immune response against the given heterologous antigen
[9]. In fact, immunization of mice with the Salmonella
enterica serovar Typhimurium aroA strain SL7207 secret-
ing C-Raf resulted in the induction of a humoral immune
response, manifested by the presence of Raf-specific anti-
bodies in some of the vaccinated mice. In addition,
C57BL/6 mice immunized with Salmonella enterica serovar
Typhimurium SL7207/pMOhly-Raf developed a Raf-spe-
cific CD8+ T-cell response. The C-Raf vaccine thus is able
to break the peripheral tolerance of the immune system
towards C-Raf and to induce a specific immune response.
Although the transgenic model is closer to the human set-
ting in comparison to challenge models with tumor cell
lines, we can not formally exclude that lung specific
expression of the transgene in our BxB model is not suffi-
cient for the induction of peripheral tolerance. Further-
more, side effects due to autoimmunity might occur in
humans who have a more generalized expression pattern.
However, the lung tissue does not belong to immunopriv-
ileged sites and we have never observed any signs of lung
pathology in immunized animals which strongly suggests
that the data could, in principle, be translated into the
human setting.
Identification of the Raf-HlyAs fusion protein by  immunoblotting Figure 2
Identification of the Raf-HlyAs fusion protein by immunoblot-
ting. Cultures of Salmonella enterica serovar Typhimurium 
SL7207 carrying the plasmids pMOhly1 (lanes 1 and 3) or 
pMOhly-Raf (lanes 2 and 4) were grown in BHI medium to a 
density of 5 × 108 cells per ml (optical cell density OD600 = 
1). Supernatant proteins precipitated from 1.5 ml of bacterial 
culture were loaded in lanes 1 and 2; cellular proteins from 
0.15 ml of culture were loaded in lanes 3 and 4. The immu-
noblot was developed with polyclonal anti C-Raf antibodies. 
The samplers were prepared as described in Materials and 
Methods.
Raf-specific IgG in sera of i.n (A) or p.o/i.v Figure 3
Raf-specific IgG in sera of i.n (A) or p.o/i.v. (B) immunized 
BxB23 mice (serum dilution 1:200) demonstrated by western 
blotting. Proteins of 106 lysed SF9 cells expressing recom-
binant C-Raf [28] (lanes marked with +) or proteins of 106 
lysed SF9 cells (– lanes) as control were loaded per lane.BMC Cancer 2005, 5:15 http://www.biomedcentral.com/1471-2407/5/15
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We demonstrated also a partial tumor protection both in
BxB23 and in BxB11 mice after immunization with
recombinant  Salmonella enterica serovar Typhimurium
SL7207/pMOhly-Raf. However, we were not able to assess
Raf specific CTL responses in these mice due to the high
variability and background and therefore we cannot con-
clude whether protection is really due to cytotoxic T-cells
or might be the result of other effects, e.g. an increased
intratumoral level of IFN-γ produced by Raf specific CD4+
T-cells. Interestingly, the observed variation occurred only
in treated BxB23 mice, not in naïve BxB23 mice. There-
fore, the observed effect might be due to a spontaneous
induction of an immune response mediated by tumor
infiltrating bacteria. It is interesting to note that spontane-
ous Raf specific immune responses also occur in the
human context, which we have recently demonstrated B-
Raf V599E specific CTL and B-Raf /B-Raf V599E specific
humoral responses in melanoma patients [24,25].
Most importantly, the lack of B-Raf V599E mutations in
metastases of melanoma patients with strong B-Raf V599E
CD8 response [24] supports the notion that CD8+ T-cells
are effective in eliminating antigen positive tumor cells.
The combined data thus provide proof of concept for the
development of Raf-based anti-cancer vaccines.
This is the first example demonstrating that the E. coli
hemolysin secretion system is a versatile tool for the
delivery of cancer antigens in Salmonella enterica serovar
Typhimurium. Moreover, we have recently shown that
this secretion system is also fully active in Salmonella enter-
ica serovar Typhi Ty21a, the only Salmonella vaccine strain
registered for human use [26]. Therefore, the combination
of the hemolysin secretion system and S. typhi Ty21a
could form the basis for a new generation of live bacterial
vaccines against cancer.
Increased frequency of IFN-γ-secreting CD8+ T cells after p.o./i.v Figure 4
Increased frequency of IFN-γ-secreting CD8+ T cells after p.o./i.v. Salmonella infection of C57BL/6 mice (n = 3). For each group, 
1 mouse was assessed individually and the remaining splenocytes from 2 mice were pooled in an equivalent proportion. 1 × 106 
spleen cells restimulated with either wild-type EL-4 (EL-4) or C-Raf overexpressing EL-4 cell (EL-Raf) and not stimulated (NST) 
were used. Production of IFN-γ was determined by flow cytometry after CD8 surface staining and intracellular IFN-γ staining. 
Each data point represents the proportion of IFN-γ positive cells for one individual mouse or two pooled mice respectively. 
Intracellular staining with an FITC-conjugated isotype control mAb always resulted in <0.05% positive cells.BMC Cancer 2005, 5:15 http://www.biomedcentral.com/1471-2407/5/15
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Conclusions
Taken together we have demonstrated that the C-Raf anti-
gen can be successfully expressed and secreted by the
attenuated Salmonella enterica serovar Typhimurium aroA
SL7207 strain via the E. coli hemolysin secretion system.
In addition, the immunization of wild-type C57BL/6 or
tumor bearing transgenic mice with this C-Raf secreting
Salmonella strain provoked specific C-Raf antibody and T
cell responses. Most importantly, the vaccine strain
induced partial protection against lung cancer in two
transgenic mouse models of Raf oncogene-induced lung
adenomas.
The approach may provide a new strategy for the rational
design of cancer therapies.
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Effect of immunization on reduction of lung weight Figure 5
Effect of immunization on reduction of lung weight. Reduc-
tion of lung weight is a mark for a delayed tumor growth. 
Lung weight of 12–13-month-old BxB23 mice immunized 
with SL7207/pMO-Raf (i.n., n = 10), SL7207/pMO Raf (p.o./
i.v., n = 8), SL7207 (i.n or p.o./i.v., n = 6) and naive (n = 6). 
Bars represent means and standard deviation of the mice per 
group. Differences in lung weight (tumor weight) between 
experimental groups treated with SL7207pMO-Raf (i.n and 
p.o./i.v.) and all control groups were statistically significant * 
(P < 0.05), as determined by Student's t test. n – number of 
the mice
Survival of naive BxB11 (■ ) or BxB11 mice immunized intra- nasally with SL7207 pMOhly-Raf (▲ ) in period of one year Figure 6
Survival of naive BxB11 (■ ) or BxB11 mice immunized intra-
nasally with SL7207 pMOhly-Raf (▲ ) in period of one year.
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